Singapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical Awards
SINGAPORE, Oct. 24, 2023 /PRNewswire/ -- Juniper Biologics , a global science-led pharmaceutical company headquartered in Singapore, has been honored with the prestigious title of the "Most Innovative Oncology Pharmaceutical Company 2023" by the Global Health & Pharma (GHP) Healthcare and Pharmaceutical Awards.
- SINGAPORE, Oct. 24, 2023 /PRNewswire/ -- Juniper Biologics , a global science-led pharmaceutical company headquartered in Singapore, has been honored with the prestigious title of the "Most Innovative Oncology Pharmaceutical Company 2023" by the Global Health & Pharma (GHP) Healthcare and Pharmaceutical Awards.
- This recognition underscores Juniper Biologics' commitment to advancing healthcare by delivering groundbreaking therapies in the field of Oncology and oncology-supportive care.
- The annual GHP Awards recognizes healthcare institutions, professionals, and trailblazers for their contributions to the remarkable progress in the healthcare and pharmaceutical fields.
- Raman Singh, CEO of Juniper Biologics, expressed his appreciation for the company's recognition as the Most Innovative Oncology Pharmaceutical Company 2023 by GHP.